Grace Therapeutics, Inc. (GRCE): auditor change — Acasti Pharma dismisses Ernst & Young, engages KPMG as new auditor

Grace Therapeutics, Inc.

Board approved dismissal of E&Y as independent auditor on Dec 11, 2023; E&Y letter filed as Exhibit 16.1.
KPMG engaged as new independent auditor for fiscal year ending Mar 31, 2024, effective same date.
No disagreements or reportable events with E&Y during fiscal 2023 or subsequent interim period.
Decision based on KPMG's US location, competitive review, and other business factors.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

Grace Therapeutics, Inc. engaged KPMG LLP (U.S.) as its auditor.

Action: engagement
Auditor: KPMG LLP (U.S.)

Exact text from the filing

On December 11, 2023, in connection with the Company’s dismissal of E&Y, the Audit Committee recommended to the Board and the Board approved the engagement of KPMG LLP (U.S.) ("KPMG") as its new independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending March 31, 2024.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

Grace Therapeutics, Inc. dismissed Ernst & Young LLP (Canada) as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP (Canada)

Exact text from the filing

Ernst & Young LLP (Canada) (“E&Y”) was previously the principal independent accounting firm for Acasti Pharma Inc. (the “Company”). On December 11, 2023, the Audit Committee (the “Audit Committee”) of the Company's Board of Directors (the “Board”) recommended to the Board and the Board approved the dismissal of E&Y as the Company’s independent registered public accounting firm. The report of E&Y on the consolidated financial statements of the Company as of and for the fiscal year ended March 31, 2023 did not contain any adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.

View on SEC.gov

56 auditor changes filed in the last 30 days. Browse all auditor changes →

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-070574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.